Literature DB >> 22112208

Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein.

Raffaella Zoe Pellicani1, Angela Stefanachi, Mauro Niso, Angelo Carotti, Francesco Leonetti, Orazio Nicolotti, Roberto Perrone, Francesco Berardi, Saverio Cellamare, Nicola Antonio Colabufo.   

Abstract

The multifactorial nature of chemotherapy failure in controlling cancer is often associated with the occurrence of multidrug resistance (MDR), a phenomenon likely related to the increased expression of members of the ATP binding cassette (ABC) transporter superfamily. In this respect, the most extensively characterized MDR transporters include ABCB1 (also known as MDR1 or P-glycoprotein) and ABCC1 (also known as MRP1) whose inhibition remains a priority to circumvent drug resistance. Herein, we report how the simple galloyl benzamide scaffold can be easily and properly decorated for the preparation of either MRP1 or P-gp highly selective inhibitors. In particular, some gallamides and pyrogallol-1-monomethyl ethers showed remarkable affinity and selectivity toward MRP1. On the other hand, trimethyl ether galloyl anilides, with few exceptions, exhibited moderate to very high and selective P-gp inhibition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22112208     DOI: 10.1021/jm201305y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Chalcogenopyrylium dyes as differential modulators of organic anion transport by multidrug resistance protein 1 (MRP1), MRP2, and MRP4.

Authors:  Robert L Myette; Gwenaëlle Conseil; Sean P Ebert; Bryan Wetzel; Michael R Detty; Susan P C Cole
Journal:  Drug Metab Dispos       Date:  2013-03-25       Impact factor: 3.922

2.  Prediction of P-glycoprotein inhibitors with machine learning classification models and 3D-RISM-KH theory based solvation energy descriptors.

Authors:  Vijaya Kumar Hinge; Dipankar Roy; Andriy Kovalenko
Journal:  J Comput Aided Mol Des       Date:  2019-11-19       Impact factor: 3.686

3.  N-(4-Bromo-phen-yl)-3,4,5-trimeth-oxy-benzamide.

Authors:  Wen Gu; Chao Qiao
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-05-05

Review 4.  Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Authors:  Gergely Szakács; Matthew D Hall; Michael M Gottesman; Ahcène Boumendjel; Remy Kachadourian; Brian J Day; Hélène Baubichon-Cortay; Attilio Di Pietro
Journal:  Chem Rev       Date:  2014-04-23       Impact factor: 60.622

5.  Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer.

Authors:  Safiulla Basha Syed; Hemant Arya; I-Hsuan Fu; Teng-Kuang Yeh; Latha Periyasamy; Hsing-Pang Hsieh; Mohane Selvaraj Coumar
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

Review 6.  Small and Innovative Molecules as New Strategy to Revert MDR.

Authors:  Laura Zinzi; Elena Capparelli; Mariangela Cantore; Marialessandra Contino; Marcello Leopoldo; Nicola Antonio Colabufo
Journal:  Front Oncol       Date:  2014-01-21       Impact factor: 6.244

7.  Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid.

Authors:  Satyakam Singh; Nagarajan Rajendra Prasad; Eduardo E Chufan; Bhargav A Patel; Yi-Jun Wang; Zhe-Sheng Chen; Suresh V Ambudkar; Tanaji T Talele
Journal:  J Med Chem       Date:  2014-05-07       Impact factor: 7.446

8.  Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.

Authors:  Francesca Carofiglio; Daniela Trisciuzzi; Nicola Gambacorta; Francesco Leonetti; Angela Stefanachi; Orazio Nicolotti
Journal:  Molecules       Date:  2020-09-14       Impact factor: 4.411

Review 9.  Piperine and Its Metabolite's Pharmacology in Neurodegenerative and Neurological Diseases.

Authors:  Shofiul Azam; Ju-Young Park; In-Su Kim; Dong-Kug Choi
Journal:  Biomedicines       Date:  2022-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.